ArticleFrontiers in immunology2022
Enhancing Mesenchymal Stromal Cell Potency: Inflammatory Licensing
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- Recent trends in modified mesenchymal stromal cells: engineering approaches and international regulatory landscape.Molecular biology reports · 2026Review
- Genetically Modified MSCs for Targeted Regeneration: Balancing Efficacy, Biosafety, and GMP Standardization.Cells · 2026Review
- Macrophage-MSCs Interplay in Orthodontic Bone Remodelling: Mechanics-Immunity-Stem Cell Axis.International dental journal · 2026Review
- N-cadherin-mimetic 3D hydrogels program pro-regenerative and immunomodulatory states in human adipose-derived mesenchymal stem cells.Scientific reports · 2025Article
- Mesenchymal stem cells and extracellular vesicles for knee osteoarthritis: clinical application, mechanism exploration and prospect.Stem cell research & therapy · 2025Review
- Harnessing cell size to separate genetically and functionally distinct dental pulp-derived mesenchymal stromal cell subpopulations.Journal of biological engineering · 2025Article
- Immunomodulatory potential of cytokine-licensed human bone marrow-derived mesenchymal stromal cells correlates with potency marker expression profile.Stem cells (Dayton, Ohio) · 2024Article
- Licensing effects of inflammatory factors and TLR ligands on the regenerative capacity of adipose-derived mesenchymal stem cells.Frontiers in cell and developmental biology · 2024Article
- Article
- Innovations in cell therapy in pediatric diseases: a narrative review.Translational pediatrics · 2023Review
- Immunomodulatory properties of mesenchymal stem cells/dental stem cells and their therapeutic applications.Cellular & molecular immunology · 2023Review
- Potency Assays for Mesenchymal Stromal Cell Secretome-Based Products for Tissue Regeneration.International journal of molecular sciences · 2023Review
- Harnessing mechanical cues in the cellular microenvironment for bone regeneration.Frontiers in physiology · 2023Review
- The Art of Stem Cell-Based Therapy.Advances in experimental medicine and biology · 2023Article
- Article
- Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Mesenchymal stromal cells (MSC) undergo functional maturation upon their migration from bone marrow and introduction to a site of injury. This inflammatory licensing leads to heightened immune regulation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.